{
  "patent_number": "US 11661612",
  "country": "US",
  "title": "How Engineered TALE Proteins Can Edit Genes",
  "original_title": "DNA-binding proteins and uses thereof",
  "summary": "This patent describes engineered DNA-binding proteins called TALEs, which are shortened and modified to precisely target and edit specific DNA sequences in cells, potentially for gene therapy.",
  "what_it_does": "This patent describes new, engineered DNA-binding proteins called Transcription Activator-Like Effectors (TALEs). These TALE proteins are designed to be \"non-naturally occurring\" (Claim 1), meaning they are not found in nature but are custom-built. The key is that they are significantly shortened: the \"N-terminal region lacks at least 152 amino acids\" and the \"C-terminal region is truncated to residue C+63\" (Claim 1). These shortened TALE proteins still contain \"two or more TALE-repeat units\" with specific \"repeat variable di-residues (RVDs)\" (Claim 1), which are like recognition codes for specific DNA letters. Some of these RVDs can even be \"atypical\" (Claim 2), allowing for new DNA targeting possibilities. These engineered proteins can also be combined with \"functional domains\" (Claim 6), such as a \"nuclease domain\" (Claim 8) to cut DNA, or a \"transcriptional activator\" (Claim 7) to turn genes on. For example, a cell could be given a polynucleotide (DNA instruction) (Claim 10) that tells it to make one of these custom TALE proteins, which then finds a specific gene, cuts it, and allows for gene editing.",
  "what_it_does_not_cover": [
    "Naturally occurring TALE proteins that have not been engineered with specific N-terminal truncations of at least 152 amino acids and C-terminal truncations to C+63.",
    "Gene editing systems that do not use TALE DNA-binding domains, such as CRISPR-Cas systems or zinc finger nucleases.",
    "TALE proteins that do not contain at least two TALE-repeat units with RVDs.",
    "Polypeptides that do not bind to DNA.",
    "Pharmaceutical compositions that do not contain either the isolated polynucleotide or the isolated cell described in the claims."
  ],
  "filed": "2019-02-12",
  "granted": "2023-05-30",
  "expires": "2039-02-12",
  "status": "active",
  "holder": "Sangamo Therapeutics",
  "holder_url": "https://patentbrief.org/company/sangamo-therapeutics",
  "inventors": [
    {
      "name": "Siyuan Tan",
      "url": "https://patentbrief.org/inventor/siyuan-tan"
    },
    {
      "name": "David Paschon",
      "url": "https://patentbrief.org/inventor/david-paschon"
    },
    {
      "name": "Philip D. Gregory",
      "url": "https://patentbrief.org/inventor/philip-d-gregory"
    },
    {
      "name": "Edward J. Rebar",
      "url": "https://patentbrief.org/inventor/edward-j-rebar"
    },
    {
      "name": "Jeffrey C. Miller",
      "url": "https://patentbrief.org/inventor/jeffrey-c-miller"
    },
    {
      "name": "Lei Zhang",
      "url": "https://patentbrief.org/inventor/lei-zhang"
    },
    {
      "name": "Fyodor Urnov",
      "url": "https://patentbrief.org/inventor/fyodor-urnov"
    }
  ],
  "times_cited": 1,
  "tags": [
    "biotech",
    "gene_editing",
    "pharmaceutical",
    "software"
  ],
  "abstract": "Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.",
  "url": "https://patentbrief.org/patent/us/11661612/dna-binding-proteins-and-uses-thereof",
  "markdown_url": "https://patentbrief.org/patent/us/11661612/dna-binding-proteins-and-uses-thereof/md",
  "google_patents_url": "https://patents.google.com/patent/US11661612",
  "relatedPatents": [
    {
      "patentNumber": "8697359",
      "countryCode": "US",
      "title": "How to Edit Genes in Human Cells Using an Engineered CRISPR System",
      "url": "https://patentbrief.org/patent/us/8697359/crispr-gene-editing"
    },
    {
      "patentNumber": "10113167",
      "countryCode": "US",
      "title": "How CRISPR-Cas9 Uses RNA to Edit DNA",
      "url": "https://patentbrief.org/patent/us/10113167/methods-and-compositions-for-rna-directed-target-dna-modification-and-for-rna-directed-modulation-of-transcription"
    },
    {
      "patentNumber": "12252707",
      "countryCode": "US",
      "title": "How to Make Animals That Can Turn On CRISPR Gene Editing",
      "url": "https://patentbrief.org/patent/us/12252707/delivery-engineering-and-optimization-of-systems-methods-and-compositions-for-se"
    },
    {
      "patentNumber": "11739322",
      "countryCode": "US",
      "title": "CRISPR Gene Editing That Turns Itself Off",
      "url": "https://patentbrief.org/patent/us/11739322/method-for-genome-editing-using-a-self-inactivating-crispr-nuclease"
    },
    {
      "patentNumber": "20180305704",
      "countryCode": "US",
      "title": "How to Use Many CRISPR Guides to Study Many Genes at Once",
      "url": "https://patentbrief.org/patent/us/20180305704/crispr-cas-component-systems-methods-and-compositions-for-sequence-manipulation"
    }
  ]
}